<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0134">Dr Bar reported on preclinical studies in chronically simian HIV (SHIV)-infected rhesus monkeys. Using bNAbs as mono or dual therapy, virus suppression, immune-modulatory effects as well as a reduction of proviral DNA in tissue reservoirs were demonstrated 
 <xref rid="JVEv5-bib-0044" ref-type="bibr">[44,45]</xref>, thereby setting the stage for human clinical trials testing.
</p>
